Block Grant R41CA128152

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $391,826 to the University of Pennsylvania on July 16, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate an innovative nanoparticle-based therapeutic platform for breast cancer treatment. The project, which extends through June 30, 2027, focuses on designing biodegradable polyphosphazene nanoparticles (PPNPs) that combine heat shock protein (HSP) inhibitor drug...

The Leland Stanford Junior University (Stanford University) has been awarded a $462,860 Project Grant from the National Cancer Institute (NCI), an institute of the U.S. Department of Health and Human Services, under the NCI's Cancer Treatment Research program (CFDA 93.395). This 5-year grant supports the development of novel targeted radionuclide therapy (TRT) approaches for the treatment of triple-negative breast cancer (TNBC). The key objectives of this project are to develop MUC1-targeted...

Federal Grant Award Summary Natsar Pharmaceuticals, Inc. received a $1.63 million Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to support the development and commercialization of RK-33, a small molecule inhibitor targeting DDX3 (DEAD-box helicase 3) for the treatment of triple-negative breast cancer (TNBC). The award, effective September 22, 2025 through August 31, 2027, funds the continued clinical development of RK-33, which...

Federal Project Grant Award Summary Chapman University received a $415,500 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded June 19, 2025, with completion targeted for May 31, 2028. The award supports research to develop peptide-doxorubicin (DOX) conjugates as improved chemotherapy delivery systems. Doxorubicin is an FDA-approved anthracycline drug used to treat multiple cancer types, but its clinical application is limited...

The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), awarded a $218,089 Project Grant to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel chimeric antigen receptor macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The project, titled "RAC-Enhanced Chimeric Antigen Receptor-Macrophage (RACE-CAR-M) Immunotherapy for Triple Negative Breast Cancer," aims to...

Federal Grant Award Summary The National Cancer Institute awarded The Methodist Hospital Research Institute a Project Grant of $403,485 under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2027. This grant supports the development of novel platinum-based reactive oxygen species (ROS)-inducing polymers designed to provide tumor-specific toxicity against triple-negative breast cancer (TNBC). The research addresses a critical clinical need, as...

This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...

GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...

This National Science Foundation (NSF) SBIR Phase I Project Grant awarded to Eascra Biotech, Inc. is focused on developing and advancing regulatory pathways for space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. The $274,990 award, granted on December 15, 2024, aims to demonstrate the comparability of space-manufactured JBNPs to earth-made counterparts, with the goal of revolutionizing cancer treatment by providing a versatile and more...

This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...